The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Background. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. Aims. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sit...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/496453 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551528886435840 |
|---|---|
| author | Takamasa Ohki Akihiro Isogawa Masahiko Iwamoto Mitsuru Ohsugi Haruhiko Yoshida Nobuo Toda Kazumi Tagawa Masao Omata Kazuhiko Koike |
| author_facet | Takamasa Ohki Akihiro Isogawa Masahiko Iwamoto Mitsuru Ohsugi Haruhiko Yoshida Nobuo Toda Kazumi Tagawa Masao Omata Kazuhiko Koike |
| author_sort | Takamasa Ohki |
| collection | DOAJ |
| description | Background. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. Aims. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. Methods. We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20). We compared the baseline characteristics, changes of laboratory data and body weight. Results. At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups. AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group. The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, 𝑃<0.01). On the other hands, the body weight significantly increased in pioglitazone group and did not change in sitagliptin group. Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12–73.1, 𝑃=0.04). Conclusions. Administration of liraglutide improved T2DM but also improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight. |
| format | Article |
| id | doaj-art-4285f42dd5c44ef7b6e2ada1640ae0d5 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-4285f42dd5c44ef7b6e2ada1640ae0d52025-02-03T06:01:09ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/496453496453The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and PioglitazoneTakamasa Ohki0Akihiro Isogawa1Masahiko Iwamoto2Mitsuru Ohsugi3Haruhiko Yoshida4Nobuo Toda5Kazumi Tagawa6Masao Omata7Kazuhiko Koike8Department of Gastroenterology, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, JapanDepartment of Diabetes and Metabolism, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, JapanDepartment of Diabetes and Metabolism, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, JapanDepartment of Diabetes and Metabolism, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, JapanDepartment of Gastroenterology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, JapanDepartment of Gastroenterology, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, JapanDepartment of Gastroenterology, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, JapanYamanashi Prefectural Hospital Organization, 1-1-1 Fujimi, Kofu City 400-8506, JapanDepartment of Gastroenterology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, JapanBackground. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. Aims. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. Methods. We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20). We compared the baseline characteristics, changes of laboratory data and body weight. Results. At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups. AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group. The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, 𝑃<0.01). On the other hands, the body weight significantly increased in pioglitazone group and did not change in sitagliptin group. Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12–73.1, 𝑃=0.04). Conclusions. Administration of liraglutide improved T2DM but also improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.http://dx.doi.org/10.1100/2012/496453 |
| spellingShingle | Takamasa Ohki Akihiro Isogawa Masahiko Iwamoto Mitsuru Ohsugi Haruhiko Yoshida Nobuo Toda Kazumi Tagawa Masao Omata Kazuhiko Koike The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone The Scientific World Journal |
| title | The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone |
| title_full | The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone |
| title_fullStr | The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone |
| title_full_unstemmed | The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone |
| title_short | The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone |
| title_sort | effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone |
| url | http://dx.doi.org/10.1100/2012/496453 |
| work_keys_str_mv | AT takamasaohki theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT akihiroisogawa theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT masahikoiwamoto theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT mitsuruohsugi theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT haruhikoyoshida theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT nobuotoda theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT kazumitagawa theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT masaoomata theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT kazuhikokoike theeffectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT takamasaohki effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT akihiroisogawa effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT masahikoiwamoto effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT mitsuruohsugi effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT haruhikoyoshida effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT nobuotoda effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT kazumitagawa effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT masaoomata effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone AT kazuhikokoike effectivenessofliraglutideinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellituscomparedtositagliptinandpioglitazone |